ArticleFrontiers in endocrinology2019
Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma.
Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).European journal of nuclear medicine and molecular imaging · 2025Guideline
- Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.The Laryngoscope · 2026Article
- Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer.European thyroid journal · 2026Article
- Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.European thyroid journal · 2025Article
- The potential role of neoadjuvant treatment in thyroid cancers in the era of kinase inhibitors: a narrative review.Endocrine · 2025Review
- The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review.Journal of clinical medicine · 2025Review
- Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.Exploration of targeted anti-tumor therapy · 2025Review
- Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.Journal of clinical medicine · 2024Review
- Article
- Response to sorafenib in a locally advanced oncocytic cell carcinoma of the thyroid.BMJ case reports · 2024Article
- Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective.Reviews in endocrine & metabolic disorders · 2024Review
- Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma.Frontiers in oncology · 2024Review
- Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAFArchives of endocrinology and metabolism · 2023Article
- Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.Frontiers in endocrinology · 2023Review
- Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review.Cancer reports (Hoboken, N.J.) · 2022Review
- Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.